20170330-AACR poster EN
Month: March 2017
Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
20170320 2016 Resultats annuels EN
First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
20170313 FPI Kelly study EN